A Spark in the Lab

Picture this: It’s 2 a.m. in a small business innovation research (SBIR) company’s lab. A young researcher, let’s call her Sarah, is hunched over a prototype. Her team has been working for months on a new medical device, funded by a federal NIH SBIR grant. After countless failures, the device finally hums to life, delivering the exact results they’d hoped for. In that moment, Sarah doesn’t just celebrate a breakthrough—she’s just “reduced her invention to practice.” But what does that mean, and why does it matter? For Sarah and thousands like her, it’s the moment that determines who owns the future of their idea—her, the SBIR company, or the government that funded it.

What Is Reduction to Practice?

At its core, reduction to practice is the moment an invention goes from being a spark in someone’s mind to a tangible reality. It’s the point where you prove your idea works. In the world of intellectual property (IP), especially for projects funded by the US government, this concept is a linchpin. It decides ownership, shapes patent rights, and defines what the government can do with your invention.

There are two ways to reduce an invention to practice:

• Actual Reduction to Practice: You build and test the invention, showing it works as intended. Think of Sarah’s device humming in the lab—that’s actual reduction to practice.
• Constructive Reduction to Practice: You file a patent application that describes the invention so clearly that someone skilled in the field could recreate it without excessive trial and error. No prototype needed, just a detailed blueprint.

Why does this matter? In government-funded research, the moment of reduction to practice can trigger a cascade of legal and financial consequences, particularly under the Bayh-Dole Act.

The Bayh-Dole Act: A Game-Changer for Innovation

Let’s step back to 1980. Before then, if you invented something with federal funding—say, a new drug or technology—the government owned it. Small businesses and universities had little incentive to innovate, as they couldn’t profit from their work. Enter the Bayh-Dole Act, a groundbreaking law that upended the status quo. It allowed small businesses, nonprofits, and universities to own and patent inventions they conceived or first reduced to practice with federal funds. This change unleashed a wave of innovation, from life-saving drugs to cutting-edge tech.

But there’s a catch: The government doesn’t just hand over the keys. It retains significant rights to these inventions, known as “subject inventions” under the Bayh-Dole Act. To understand these rights, we need to dive into how reduction to practice plays a role.

How Reduction to Practice Shapes Ownership

Imagine Sarah’s medical device again. Her team utilized a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support their research. Under Bayh-Dole, if the invention was conceived (the idea was born) or first reduced to practice (proven to work) with federal funds, it’s a subject invention. This classification means Sarah’s SBIR company can own the patent, but only if they follow strict rules. Here are the key disclosure and reporting requirements for subject inventions under SBIR:

• Employee Agreement: Awardee organizations must have a written agreement with all employees to promptly disclose any subject invention made under a federally sponsored program.
• Prompt Reporting: Subject inventions must be reported to the funding agency (such as NIH, NSF, DOE, etc.) within two months after the inventor discloses it in writing to the organization’s personnel responsible for patent matters.
• iEdison Reporting: Companies must report inventions through the iEdison system (the federal electronic reporting portal for invention disclosures).
• Election of Title: The awardee must elect to retain ownership of the subject invention within a set time frame, generally within two years of disclosure to the agency. If the organization does not make this election, the government may take title to the IP.
• Patent Filing: The awardee must file a patent application (if it elects to retain title) within one year of election.
• Federal Interest Clause: Patent applications must acknowledge government support with a federal funding clause.
• Government License: The government receives a non-exclusive, non-transferable, irrevocable, paid-up license to practice or have practiced the subject invention worldwide.
• Reporting Utilization: The awardee must provide annual reports on the utilization and commercialization status of the invention, including commercialization dates and royalties received.
• March-In Rights: The government retains “march-in rights” to ensure inventions are made available to the public under certain circumstances. As of the time of writing this article, research has not revealed a single instance where the government has exercised these rights.
• Preference for US Industry: Exclusive licensees must substantially manufacture the invention in the US if it will be used or sold in the US.

Key points:

• Disclosure and reporting of all subject inventions must be made, whether or not a patent is filed.
• Timely disclosure is essential; failure to comply can result in the loss of rights to the invention.

If Sarah’s team reduces the invention to practice using private funding after the federal SBIR grant ends, it might not be a subject invention. However, proving this is challenging; the company must have every lab notebook, email, and receipt demonstrating that no federal dollars were involved. These records include accounting records that show no government funding was used. One misstep, and the government can claim rights.

The Government’s Slice of the Pie

Even when the SBIR company owns the patent, the government receives a portion of the proceeds. Here’s what they hold:

• Nonexclusive License: The government can use the invention for its own purposes—think military or public health—without paying royalties. For Sarah’s device, this might mean the Veterans Administration uses it in hospitals.
• March-In Rights: If the SBIR company doesn’t commercialize the invention or make it available to the public, the government can “march in” and force them to license it to others. This use of march in rights is rare but powerful, especially for inventions related to health.
• Title Reversion: If the SBIR company fails to disclose the invention or meet Bayh-Dole’s deadlines, the government can take ownership outright.
• US Manufacturing Preference: The SBIR company must prioritize manufacturing the invention in the US, unless the NIH grants a waiver.

These rights ensure taxpayer-funded research benefits the public, but they also create a delicate dance for researchers like Sarah. Every step—conception, reduction to practice, and patent filing—must be meticulously documented.

Real-World Stakes: A Tale of Two Inventions

To see the reduction to practice in action, let’s look at two real-world examples. In the 1990s, researchers at a small business developed a groundbreaking HIV drug with NIH funding. They reduced it to practice during the SBIR grant period, making it a subject invention. The company patented it, licensed it to a pharmaceutical company, and it became a global lifesaver. The government got its nonexclusive license, and the public benefited from accessible treatment—a win-win.

Consider a less favorable scenario. Campbell Plastics Engineering & Manufacturing Inc. developed technology under a US Army contract. The company failed to properly disclose the invention as required under Bayh-Dole and federal regulations. Subsequently, they filed a patent application. The Army asserted ownership due to the disclosure failure, and the US Court of Appeals for the Federal Circuit upheld the government’s claim, resulting in the company losing its patent.

Key details:

• Campbell Plastics failed to report a subject invention developed under a federal contract in a timely manner.
• After the patent was issued, the Army requested the title due to noncompliance with disclosure duties.
• The Federal Circuit affirmed the forfeiture of patent rights to the government.

These stories show that reduction to practice isn’t just a technical term. It’s a make-or-break moment for innovators and companies.

Why It’s Harder Than It Sounds

Reduction to practice sounds simple: Build it or describe it. But in practice, it’s a minefield. For one, proving when and how an invention gets reduced to practice requires meticulous record-keeping. Was the prototype built with federal funds? Did the idea evolve after the SBIR grant ended? These questions can spark legal battles. So, documentation and accurate accounting records are critical.

Then there’s the pressure to commercialize. Bayh-Dole encourages recipients to turn inventions into products, but if Sarah’s SBIR company can’t find a manufacturer or delays development, the government’s march-in rights loom. And while march-in rights remain unexercised at this time, they serve as a constant reminder of the government’s oversight.

Finally, the global landscape adds complexity. Bayh-Dole’s US manufacturing preference can clash with today’s global supply chains. If Sarah’s device needs parts made abroad, her SBIR company must navigate a waiver process, which may not be granted.

Your Role in the Innovation Ecosystem

So, what can you do? Whether you’re a researcher, entrepreneur, or just curious, understanding reduction to practice empowers you to navigate the world of government-funded innovation. Here are three steps to start:

1. Keep Impeccable Records: Document every stage of your work—ideas, experiments, funding sources. A lab notebook or timestamped email could save your patent.
2. Know Your Obligations: If you’re working with federal funds, read up on Bayh-Dole. Your SBIR company’s tech transfer office or legal team can help, but don’t assume they’ll catch everything.
3. Think Beyond the Lab: Reduction to practice is just the beginning. Develop a robust commercialization plan early in your project. Take the time to find partners, explore licensing options, and prioritize public benefit.

For the rest of us, supporting policies like Bayh-Dole ensures that taxpayer-funded research continues to fuel breakthroughs. Next time you hear about a new drug or technology, ask: How did it get from the lab to the world? Chances are, the reduction to practice was the turning point.

The Spark That Changes Everything

Remember, back in that lab at 2 a.m., Sarah didn’t just prove her device worked—she set the stage for a ripple effect. Her invention could save lives, create jobs, or inspire the next generation. But it all hinged on that moment of reduction to practice, the point where an idea became real. In the world of government-funded research, that’s the spark that lights the way. So, what’s your spark? And how will you prove it works?

Disclaimer

The information provided in this article is for general informational purposes only and does not constitute legal, tax, financial, or professional advice. Readers should not rely on this content as a substitute for professional guidance. Always consult a qualified professional, such as a licensed attorney, accountant, or financial advisor, for advice tailored to your specific circumstances. The author and publisher are not responsible for any actions taken based on the information in this article.

1e50343b0933b9eff8dde0d57549ed56